If you have been reading about hGH fragment and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-07-24. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Jurewizc further argues that the rest of the twelve nidanas show similarities with the terms and ideas found in Vedic cosmogeny, especially as it relates to the sacrificial fire (as a metaphor for desire and existence). These Vedic terms may have been adopted by the Buddha to communicate his message of not-self because his audience (often educated in Vedic thought) would understand their basic meaning. According to Jurewizc, dependent origination replicates the general Vedic creation model, but negates its metaphysics and its morals. Furthermore, Jurewizc argues that:This deprives the Vedic cosmogony of its positive meaning as the successful activity of the Absolute and presents it as a chain of absurd, meaningless changes which could only result in the repeated death of anyone who would reproduce this cosmogonic process in ritual activity and everyday life.According to Gombrich, the Buddhist tradition soon lost sight of their connection with the Vedic worldview that the Buddha was critiquing in the first four links of dependent origination. Though it was aware that at the fourth link there should be an appearance of an individual person, the Buddhist tradition equated rupa with the first skandha, and nama with the other four skandhas. Yet, as Gombrich notes, samkhara, vijnana, and vedana also appear as separate links in the twelvefold list, so this equation can't be correct for this nidana.
Heat shock proteins (HSPs) are a family of proteins produced by cells in response to exposure to a stressor. They were first described in relation to the heat shock response, but are now known to also be expressed during other stresses including exposure to cold, UV light and during wound healing or tissue remodeling. Many members of this group perform chaperone functions by stabilizing new proteins to ensure correct folding or by helping to refold proteins that were damaged by the cell stress. This increase in expression is transcriptionally regulated. The dramatic upregulation of the heat shock proteins is a key part of the heat shock response and is induced primarily by heat shock factor (HSF). HSPs are found in virtually all living organisms, from bacteria to humans. Heat shock proteins are named according to their molecular weight. For example, Hsp60, Hsp70 and Hsp90 (the most widely studied HSPs) refer to families of heat shock proteins on the order of 60, 70 and 90 kilodaltons in size, respectively. The small 8-kilodalton protein ubiquitin, which marks proteins for degradation, also has features of a heat shock protein. A conserved protein binding domain of approximately 80 amino-acid alpha crystallins are known as small heat shock proteins (sHSP).
Letrozole and anastrozole are aromatase inhibitors which have been shown to be superior to tamoxifen for the first-line treatment of breast cancer in postmenopausal women. Exemestane is an irreversible "aromatase inactivator" which is superior to megestrol acetate for treatment of tamoxifen-refractory metastatic breast cancer, and does not appear to have the osteoporosis-promoting side effects of other drugs in this class. Aminoglutethimide inhibits both aromatase and other enzymes critical for steroid hormone synthesis in the adrenal glands. It was formerly used for breast cancer treatment, but has since been replaced by more selective aromatase inhibitors. It can also be used for the treatment of hyperadrenocortical syndromes, such as Cushing's syndrome and hyperaldosteronism in adrenocortical carcinoma.
The World Organization of the Scout Movement (WOSM ), branded as World Scouting since 2024, is the largest and, after the Order of World Scouts (formed in 1911), is the second-oldest international organisation in the Scout Movement, having been established in 1922 as The International Conference of the Boy Scout Movement. It has 176 members. These members are national scout organisations that founded WOSM or have subsequently been recognised by WOSM, which in 2025 collectively have around 51.4 million participants (up from 43 million in 2022), and a reach of 60 million young people. Its operational headquarters is in Kuala Lumpur, Malaysia, although it is legally based in Geneva, Switzerland. WOSM's stated mission is "to contribute to the education of young people, through a value system based on the Scout Promise and Scout Law, to help build a better world where people are self-fulfilled as individuals and play a constructive role in society". WOSM operates through conferences of its member organisation representatives, its committee and its full-time bureau, structured into regions. It is associated with three World Scout Centres. A World Scout Jamboree is held approximately every four years under its auspices and it organizes World Scout Moots for 17- to 26-year-olds and previously organised World Scout Indabas, a gathering for Scout leaders. The World Scout Foundation is a separately governed fund, supported by donations, for the development of WOSM associated programmes. WOSM is the counterpart of the World Association of Girl Guides and Girl Scouts (WAGGGS).
This increased demand is met by an increase in the stroke volume of the octopus' heart. The octopus does sometimes swim throughout the water, exposing itself completely. In doing so, it uses a jet mechanism that involves creating a much higher pressure in its mantle cavity that allows it to propel itself through the water. As the common octopus' heart and gills are located within its mantle, this high pressure also constricts and puts constraints on the various vessels that are returning blood to the heart. Ultimately, this creates circulation issues and is not a sustainable form of transportation, as the octopus cannot attain an oxygen intake that can balance the metabolic demands of maximum exertion.
Sources: en.wikipedia.org
Moscow is first mentioned in chronicles in the year 1147, as part of the principality of Rostov-Suzdal, which emerged from the disintegration of Kievan Rus'. Moscow was referred to as a meeting place for Yuri Dolgorukiy and Sviatoslav Olgovich. At the time, it was a minor town on the western border of the principality. The importance of Moscow increased significantly during the second half of the 12th century, and the town was converted into a fortified gorod (stronghold) during the 1150s, when the first walls of the Kremlin were built. During the Mongol invasions of 1237–1238, Moscow was sacked following the destruction of Ryazan. The first prince of Moscow was Daniel, the youngest son of Alexander Nevsky. In 1263, Daniel was given Moscow as an otchina (hereditary land), where he established a local branch of Rurikid princes. Two chronicles refer to Mikhail Khorobrit as "Mikhail of Moscow" during the mid-13th century, but Daniel is generally considered to be the first prince of Moscow. On Mikhail's death in 1248—if it is assumed that an appanage principality was created (as a grant to a younger child of a monarch)—Moscow reverted as an escheat (where the state takes ownership of "unowned" land) to the grand prince of Vladimir. Until 1271, the principality was ruled by the governors of Daniel's uncle Yaroslav, who was given Tver as an appanage. Daniel is first mentioned in chronicles in the year 1282, when he participated in a feudal war between his two older brothers.
Although the introduction of ACE inhibitors and beta blockers has improved the management of chronic heart failure, the disease continues to be an enormous medical and societal burden, with 30 to 40% of patients dying within a year of receiving the diagnosis.
== Implications in health and industry == Quorum sensing bacteria within the human microbiome are responsible for many diseases including sinusitis, otitis media, pneumonia, bacteraemia, osteomyelitis, septic arthritis, and meningitis. In the United States alone there is a death toll of >22,000 a year tracing back to this pathogen. S. pneumoniae uses the competence stimulating peptide and quorum sensing to initiate its attack, establish an infection, and develop antibiotic resistance genes. Overall, competence stimulating peptide allows S. pneumoniae to initiate a more pervading attack on the human host. Currently in health and industry, studies center on explaining and intercepting the competence region within the S. pneumoniae. The goal is to limit cell–cell communication with the hopes of attenuating S. pneumoniae infectivity. Inhibiting the competence stimulating peptide shows potential as a way to combat pneumococcal infections.
Nandrolone, also known as 19-nortestosterone (19-NT) or as estrenolone, as well as estra-4-en-17β-ol-3-one or 19-norandrost-4-en-17β-ol-3-one, is a naturally occurring estrane (19-norandrostane) steroid and a derivative of testosterone (androst-4-en-17β-ol-3-one). It is specifically the C19 demethylated (nor) analogue of testosterone. Nandrolone is an endogenous intermediate in the production of estradiol from testosterone via aromatase in mammals including humans and is present in the body naturally in trace amounts. It can be detected during pregnancy in women. Nandrolone esters have an ester such as decanoate or phenylpropionate attached at the C17β position.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.